Education
About Us
Working with TipRanks
Follow Us
Celcuity (CELC)
NASDAQ:CELC
Top Page
Celcuity
(NASDAQ:CELC)
44Neutral
Positive Factors
Clinical Trial Progress
The Phase III VIKTORIA-1 trial is enrolling patients with a relatively healthier profile compared to previous trials, allowing for a potentially more favorable treatment outcome.
Financial Stability
Celcuity ended the fourth quarter with $235 million, supporting operations through 2026.
Regulatory Progress
Gedatolisib has a breakthrough designation, leading to frequent interactions with the FDA.
Negative Factors
Financial Performance
The company reported no revenues and a net loss of $1.10 per diluted share for 4Q24, compared to consensus estimate of no revenues and a net loss of $0.71 per diluted share.
Market Sentiment
Short interest in the stock is relatively high at 15% of the float.
Celcuity (CELC) vs. S&P 500 (SPY)
Market Cap
$412.45M
Dividend YieldN/A
Average Volume (3M)328.45K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS Growth-4.14%
CountryUS
Employees87
SectorHealthcare
Sector Strength60
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding37,839,394
10 Day Avg. Volume199,965
30 Day Avg. Volume328,448
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.97K
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$30.00Price Target Upside176.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Celcuity Business Overview & Revenue Model
Company DescriptionCelcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
How the Company Makes MoneyCelcuity generates revenue primarily through the commercialization of its CELsignia platform. The company's revenue model is based on partnerships with pharmaceutical companies and healthcare providers who utilize its diagnostic tests to optimize cancer treatment strategies. Celcuity collaborates with pharmaceutical firms to enhance the efficacy of their targeted therapies, potentially sharing in the economic benefits of improved treatment outcomes. Additionally, the company may receive payments for conducting clinical trials and providing diagnostic services to institutions focused on personalized cancer treatment.
Celcuity Financial Statement Overview
Summary
Celcuity's financial performance reflects the challenges of early-stage biotech firms. The income statement shows consistent losses with no revenue, leading to a score of 10. Despite a stable balance sheet with low debt and strong liquidity, the declining equity is a concern, resulting in a score of 40. Persistent negative free cash flow due to high cash burn further impacts the score, with cash flow scoring 30. Overall, financial stability is challenged by high operational expenses and no revenue generation.Income Statement
Celcuity's income statement shows consistent losses with no revenue generation over multiple years, which is common in biotech firms during early stages. The company has high negative EBIT and net income, reflecting significant R&D and operational expenses without revenue offset. The lack of revenue growth and profitability margins poses a challenge to financial stability.―
Balance Sheet
The balance sheet indicates a stable equity base and low debt levels, with a debt-to-equity ratio of 0.002 in 2024. The company has substantial cash reserves compared to its liabilities, indicating a strong liquidity position. However, the declining equity and increasing liabilities over time can be a concern if the trend continues without revenue growth.40
Cash Flow
The cash flow statement reveals persistent negative free cash flow, indicating high cash burn due to operational activities. However, the company has managed to secure financing, as shown by strong positive financing cash flows, which provide necessary liquidity. The free cash flow to net income ratio remains negative, highlighting inefficiencies in cash generation relative to net losses.―
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -142.77K | -210.92K | -303.24K | -385.59K | -339.00K | EBIT |
| -66.23M | -39.39M | -28.36M | -9.56M | -7.81M | EBITDA |
| -58.31M | -39.18M | -28.05M | -9.17M | -7.47M | Net Income Common Stockholders |
| -63.78M | -41.35M | -30.56M | -9.09M | -7.02M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 180.58M | 168.59M | 84.29M | 11.64M | 18.74M | Total Assets |
| 191.22M | 175.70M | 85.91M | 12.96M | 20.28M | Total Debt |
| 37.45M | 35.24M | 14.89M | 262.49K | 256.14K | Net Debt |
| 6.78M | 10.67M | -69.40M | -11.38M | -18.48M | Total Liabilities |
| 51.45M | 41.93M | 17.20M | 1.25M | 983.23K | Stockholders Equity |
| 139.77M | 133.77M | 68.71M | 11.70M | 19.30M |
| Cash Flow | Free Cash Flow | |||
| -53.91M | -36.17M | -20.39M | -7.24M | -6.38M | Operating Cash Flow |
| -53.81M | -36.01M | -20.31M | -7.15M | -6.00M | Investing Cash Flow |
| -5.01M | -144.03M | -81.40K | -89.37K | 8.53M | Financing Cash Flow |
| 64.91M | 120.33M | 93.04M | 137.97K | 259.31K |
Celcuity Technical Analysis
Neutral
10.85
Price Trends
10.13
Positive
11.23
Negative
13.35
Negative
Market Momentum
0.27
Negative
55.77
Neutral
38.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELC, the sentiment is Neutral. The current price of 10.85 is above the 20-day moving average (MA) of 10.22, above the 50-day MA of 10.13, and below the 200-day MA of 13.35, indicating a neutral trend. The MACD of 0.27 indicates Negative momentum. The RSI at 55.77 is Neutral, neither overbought nor oversold. The STOCH value of 38.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CELC.
Celcuity Risk Analysis
Celcuity disclosed 47 risk factors in its most recent earnings report. Celcuity reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celcuity Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $444.37M | ― | -59.86% | ― | -95.31% | 18.58% | |
52 Neutral | $5.35B | 3.83 | -41.61% | 2.85% | 17.10% | 1.22% | |
46 Neutral | $464.76M | ― | -147.48% | ― | ― | -4.53% | |
44 Neutral | $413.52M | ― | -24.68% | ― | ― | ― | |
44 Neutral | $412.45M | ― | -87.54% | ― | ― | -4.14% | |
43 Neutral | $403.05M | ― | -54.73% | ― | ― | 7.15% | |
42 Neutral | $359.26M | ― | -81.91% | ― | 496.00% | 27.50% |
* Healthcare Sector Average
Performance Comparison
CELC
Celcuity
10.85
-6.99
-39.18%
ALT
Altimmune
5.43
-1.93
-26.22%
AUTL
Autolus Therapeutics
1.33
-2.75
-67.40%
ORIC
Oric Pharmaceuticals
5.70
-3.67
-39.17%
ABVX
Abivax SA Sponsored ADR
7.12
-7.83
-52.37%
RAPP
Rapport Therapeutics, Inc.
10.98
-15.21
-58.08%
Celcuity Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q4-2024)
| % Change Since: 7.32%|
Next Earnings Date:May 19, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical development programs and strong financial positioning, offset by increased net loss and expenses. The promising clinical data and potential for blockbuster revenue suggest a positive outlook.Q4-2024 Updates
Positive Updates
Progress in Clinical Development Programs
Celcuity completed enrollment of the PIK3CA wild-type cohort in the VIKTORIA-1 Phase III study and selection of approximately 200 sites for the VIKTORIA-2 Phase III study. The Phase Ib dose escalation study for prostate cancer is ongoing and on track for preliminary data by mid-2025.
Potential Blockbuster Revenue
Celcuity estimates that nearly 200,000 late-stage cancer patients globally could be eligible for treatment with gedatolisib, potentially generating blockbuster revenue if regulatory approvals are obtained.
Encouraging Overall Survival Data
Preliminary overall survival data from the Phase Ib study showed promising results, with median overall survival of 77 months for first-line patients and 34 months for second-line patients, compared favorably to published data.
Strong Financial Position
Celcuity ended fiscal 2024 with $235.1 million in cash, cash equivalents, and short-term investments, an increase of $54.5 million from the previous year.
Negative Updates
Increased Net Loss
Celcuity reported a net loss of $36.7 million for Q4 2024, up from $18.8 million in Q4 2023. The full-year net loss for 2024 was $111.8 million, compared to $63.8 million in 2023.
Higher R&D and Administrative Expenses
Research and development expenses increased to $33.5 million in Q4 2024 from $18.1 million in Q4 2023. G&A expenses also rose to $3 million from $1.6 million in the same period.
Company Guidance
During the Celcuity Fourth Quarter and Full Year 2024 Financial Results Webcast Conference Call, several key metrics were discussed. The company reported a net loss of $36.7 million, or $0.85 per share, for the fourth quarter, compared to $18.8 million, or $0.65 per share, in the same period the previous year. For the full year 2024, the net loss totaled $111.8 million, or $2.83 per share, up from $63.8 million, or $2.69 per share, in 2023. The non-GAAP adjusted net loss for Q4 2024 was $32.3 million, or $0.75 per share, compared to $17.6 million, or $0.61 per share, in Q4 2023. For the full year, the non-GAAP adjusted net loss was $101.9 million, or $2.58 per share, versus $57.8 million, or $2.44 per share, in 2023. Research and development expenses rose to $33.5 million for the fourth quarter and $104.2 million for the year, driven by ongoing clinical trials. Celcuity ended the year with $235.1 million in cash and equivalents, up from $180.6 million at the end of 2023, following financing activities that raised $138.4 million.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.